Labcorp Introduces 10-Minute Fentanyl Detection Test

Labcorp has launched the Labcorp Fentanyl Urine Visual Test, the first U.S. Food and Drug Administration (FDA)-cleared rapid fentanyl test of its kind that delivers results in 10 minutes. The assay gives healthcare providers fast, actionable answers when treating suspected fentanyl exposure in emergency departments, hospitals, and clinics.

Fentanyl exposure remains a concern across acute care and clinical settings. Labcorp data show that between 2024 and 2025, approximately 4% of pre-employment screenings tested positive for fentanyl, and nearly 10% of patients receiving opioid use disorder treatment tested positive. Recent guidance from the Association for Diagnostics and Laboratory Medicine (ADLM) also highlights the importance of reliable screening tools in emergency care, particularly as synthetic opioids like fentanyl become more prevalent.

“When clinicians suspect fentanyl exposure, they need quick, dependable answers to inform care,” Labcorp Chief Scientific and Medical Officer Dr. Brian Caveney said. “The Labcorp Fentanyl Urine Visual Test delivers results in minutes, helping teams respond quickly and confidently in emergency departments, hospitals, and clinics—ultimately supporting better patient outcomes.”

Test Features

The test assesses fentanyl exposure by detecting norfentanyl—the primary fentanyl metabolite—which can remain present in urine up to 48 hours after initial exposure. This provides a longer detection window than fentanyl itself, which may clear within hours. The test is FDA-cleared for use by qualified professionals in Clinical Laboratory Improvement Amendments (CLIA)-certified settings. Results are intended for preliminary rapid screening purposes and should be confirmed using appropriate laboratory methods, per the standard practice for rapid testing.

The Labcorp Fentanyl Urine Visual Test is available through Labcorp Point of Care, previously known as MEDTOX Diagnostics. Throughout 2026, product names, packaging, and resources will transition from MEDTOX Diagnostics to Labcorp Point of Care.

Labcorp offers laboratory services that help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear, confident decisions. The company’s nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and perform more than 750 million tests annually for patients around globally.